Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer
Evaluation of Obstructive Sleep Apnea in Head and Neck Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ammar Sukari, M.D.
- Phone Number: 313-576-8778
- Email: sukaria@karmanos.org
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Locally advanced (stage III-IVb) and metastatic (stage IVc) HNSCC who are referred to medical oncology. Patients may not have received upfront definitive surgical resection of the primary tumor or upfront neck dissection.
- Patients must be able to operate the home sleep study device.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Exclusion Criteria:
- Patients should not have received any prior systemic chemotherapy or radiation therapy for locally advanced or metastatic HNSCC.
- Patients with tracheostomy or those requiring the assistance of a ventilator will be ineligible for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Monitoring device, Quality of Life Assessment, Questionnaire
Patients wear the home sleep apnea machine overnight.
Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
|
Ancillary studies
Ancillary studies
Patients wear the home sleep apnea machine overnight.
Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Obstructive sleep apnea (OSA) rate before and after chemoradiation therapy (CRT) in stage III-IVb patients undergoing CRT
Time Frame: Up to 1 year
|
The definition of OSA will be defined as apnea-hypopnea index of > 5 for both pre and post CRT.
The OSA rate is the proportion of patients diagnosed with OSA.
Will be assessed using a two-sided McNemar test based on the OSA occurrence (Yes versus [vs.]
No) for each patient.
The OSA rates pre and post CRT will be described by means and their two-sided confidence intervals (Cls).
The univariable and multivariable conditional logistic regression models will be further used for the primary objective with patients' baseline characteristics as covariates.
|
Up to 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response to CRT
Time Frame: Up to 1 year
|
Will be evaluated using Response Evaluation Criteria in Solid Tumors version 1.1.
Will be described by mean and the two-sided CI.
The univariable and multivariable binary (multinomial) logistic regression models will be used to assess the association of the effects of patients' baseline characteristics and the occurrence of OSA on the CRT responses.
|
Up to 1 year
|
|
Occurrence of OSA in stage III-IVb patients undergoing CRT
Time Frame: Up to 1 year
|
Will be grouped into four categories (Yes/Yes, Yes/No, No/Yes, and No/No for pre/post CRT).
Then a 2x4 contingency table will be generated by CRT response (binary; Yes vs. No) and OSA occurrence (quaternary; Yes/Yes vs. Yes/No vs. No/Yes vs. No/No) and a Chi- 23 squared test (or Fisher's exact test) will be used.
The univariable and multivariable binary (multinomial) logistic regression models will be used to assess the association of the effects of patients' baseline characteristics and the occurrence of OSA on the CRT responses.
|
Up to 1 year
|
|
OSA rate in locally advanced or metastatic stage head and neck squamous cell carcinoma (HNSCC) patients
Time Frame: Up to 1 year
|
A descriptive analysis will be performed on all patients enrolled and on all eligible patients who undergo home sleep apnea study to evaluate the OSA rate in locally advanced or metastatic stage HNSCC patients.
The OSA rate will be estimated for locally advanced or metastatic stage HNSCC patients who enter the study in Part 1 and then will be described by mean and the two-sided Cl.
|
Up to 1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence rate to OSA treatment to 30 days
Time Frame: Up to 1 year
|
It is defined as the ratio of the number of days adhered to OSA treatment to 30 days.
|
Up to 1 year
|
|
Incidence rate of OSA by MRI neck findings
Time Frame: Up to 1 year
|
It is the OSA rate detected by MRI neck findings among oropharyngeal cancer patients.
|
Up to 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ammar Sukari, M.D., Barbara Ann Karmanos Cancer Institute
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Apnea
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Squamous Cell
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Head and Neck Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
Other Study ID Numbers
Other Study ID Numbers
- 2017-135
- P30CA022453 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.